In the developed world, AMD is the most prevalent cause of legal blindness in older individuals 1,2 . AMD is a progressive disease charac terized by the accumulation of focal extracellular deposits on the Bruch's membrane below the retinal pigment epithelium (RPE) in the macula, which is recognized in an eye examination as drusen. The presence of drusen in the macula, the density of the deposits and the area covered by this material are used to define the early stages in the AMD disease process. Individuals with drusen are considered at risk for progressing to the endstage blinding forms of AMD [3] [4] [5] . Geographic atrophy, the end stage of the atrophic 'dry' form of AMD, culminates in vision loss after focal degeneration of the RPE below the fovea 6 . Without the RPE, the foveal cone photoreceptors degenerate, causing central retinal blindness. CNV characterizes the end stage of the exudative 'wet' form of AMD, with new blood vessels breaking through the Bruch's membrane and the RPE that then hemorrhage, causing a blood clot to form between the RPE and the foveal photo receptors, resulting in immediate blindness 3, 4 .
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AMD is classically multifactorial, involving both environmen tal and genetic factors 7 . Sequence variants associated with disease susceptibility have now been characterized in a growing number of immuneregulated genes [8] [9] [10] [11] . Activation of complement on ocular surfaces is thought to have a major role in the early disease pro cess and results in drusen deposition. However, the mechanisms involved in the initiation of the inflammatory responses observed in the eyes of subjects with AMD are unresolved.
Drusen deposits are particulate protein aggregates that are extra cellular in nature. These characteristics typify known activators of the sterile inflammatory response that is mediated by NLRP3. NLRP3 acts as a receptor for 'danger' signals, such as ATP, uric acid crystals, amyloidlike structures and mitochondrial dysfunction [12] [13] [14] [15] . These danger signals activate the inflammasome, which is made up of NLRP3, apoptosisassociated specklike domain containing a caspaserecruitment domain (ASC) and pro-caspase1, resulting in the cleavage of pro-IL1β and pro-IL18 into their mature proinflammatory forms. Furthermore, excessive drusen accumulation can disrupt adjacent RPE cells, which subsequently die by necrosis 16 , a cellular process now known to activate the NLRP3 inflammasome 17 .
Here we show that drusen isolated from AMD donor eyes can activate the NLRP3 inflammasome. Furthermore, we show that CEP, an oxida tive stress-related protein modification commonly found decorating drusen proteins 18, 19 , can prime the inflammasome. In tandem, we show that the complement component C1Q can activate the NLRP3 inflam masome in a caspase1-dependent and phagolysosomedependent manner. We observed activated caspase1 and NLRP3 in macro phages surrounding the drusenlike lesions in mice immunized with CEPadducted mouse serum albumin (CEPMSA), which is a model of dry AMD. We also found that NLRP3 affects disease in a mouse model of wet AMD 20, 21 . In the absence of NLRP3 in this model, CNV development was exacerbated. We implicate IL18 as a key regulator of pathological neovascularization and suggest a protective role for the NLRP3 inflammasome in the development of AMD.
RESULTS
The RPE is a monolayer of cuboidal cells located between the outer retina and the choroid. This melanized neuroepithelium has numer ous functions, including (i) the adsorption of scattered and reflected light, (ii) the formation of the outer bloodretinal barrier and (iii) the removal by phagocytosis of the effete tips of the photoreceptor outer segments 22 . Proteomic and immunohistochemical analyses of drusen have identified virtually every protein involved in the complement cas cade and the proteins found in amyloid deposits, as well as a number of crystallins, which are proteins synthesized in response to stress 23, 24 . Considering the recent discovery that hostderived particulate matter such as cholesterol crystals and amyloid deposits 25, 26 can activate the NLRP3 inflammasome, we were interested in determining whether drusen could also initiate the activation of the inflammasome.
Drusen activates the NLRP3 inflammasome
We first used fundus photography to compare an unaffected eye to the eyes of individuals with either dry or wet AMD (Fig. 1a) . We found punctate light deposits in the fundus images of the eyes with wet and dry AMD, representing drusen accumulation, and we found subretinal CNV in the image of the eye with wet AMD. We sonicated the isolated drusen to dissociate the sample into small particulate matter (Fig. 1b) . An SDSPAGE analysis of the drusen sample showed a cohort of proteins of high molecular weight (greater than 60 kDa) (Fig. 1c) .
The inflammasome is a multimeric protein complex. Caspase1 is the cysteine protease that is activated in the inflammasome com plex to cleave pro-IL1β and pro-IL18 into their mature forms. Activation of caspase1 requires the protein ASC, which forms oli gomers to create a platform for the multimeric complex. Normally, ASC is evenly distributed throughout the cell, but once activated, ASC aggregates to a single point known as a 'speck' . We primed bone marrow-derived macrophages (BMDMs) that stably express yellow fluorescent protein-labeled ASC (YFPASC) with lipopolysaccha rides (LPSs) and treated them with drusen or transfected them with poly(dAdT) (positive control). ASCYFP was difficult to discern in macrophages treated with LPS alone (Fig. 1d) , however, in LPS primed macrophages activated with drusen, the formation of intense single fluorescent specks was clearly evident, which is indicative of ASC oligomerization.
The inflammatory response associated with AMD has both a local and a systemic component. We initially tested the ARPE19 cell line for the presence of NLRP3 and for the ability of the cells to produce IL1β in response to a range of Tolllike receptor (TLR) ligands and activation with ATP. We found that although ARPE19 cells express NLRP3, the amount of IL1β in these cells was at the lower limit of the assay sensitivity (Supplementary Fig. 1 ). Because of their ability to access the retina in AMD, peripheral myeloid cells are probably the primary source of IL1β and IL18. We there fore hypothesized that these cells would be key cells of interest in our system. Human peripheral blood mononuclear cells (PBMCs) produced IL1β and IL18 in response to activation with drusen, even at very low concentrations (Fig. 1e,f) . We used RPE mate rial that was produced during the dissection of drusen from AMD eyes as a control for these experiments (Supplementary Fig. 2 ). the human monocytic cell line THP1 after treatment with drusen confirmed increased amounts of the cleaved caspase1 subunit p10 ( Fig. 1g and Supplementary Fig. 3 ). Together, these results show that drusen from AMD donor eyes can activate caspase1 and the ASC inflammasome complex, which in turn results in IL1β and IL18 production in PBMCs. We reasoned that NLRP3 was the probable sensor for drusen induced inflammasome activation, as it is required for inflamma some activation by particulate matter. We isolated bone marrow from both wildtype (WT) and NLRP3deficient (Nlrp3 −/− ) mice and then used the bone marrow to culture BMDMs and bonemarrow-derived dendritic cells (BMDCs). WT BMDMs and BMDCs produced signifi cantly higher amounts of IL1β in response to drusen than Nlrp3 −/− BMDMs and BMDCs (Fig. 1h,i ), which were unable to promote the production of mature IL1β in response to drusen. The amounts of IL6 and tumor necrosis factor α (TNFα) were unaltered by the pres ence of drusen, which is indicative of a specific effect of drusen on IL1β production (Fig. 1h,i) . These results show that AMD drusen are capable of activating the NLRP3 inflammasome.
CEP-adducted human serum albumin primes the inflammasome Up to 65% of the proteins that have been identified in drusen were found in drusen isolated from both AMD and nondiseased donors. However, oxidative protein modifications have also been observed in drusen, including CEP protein adducts. Cumulative oxidative damage contributes to aging and has long been suspected to contribute to the pathogenesis of AMD [27] [28] [29] . CEP adducts are uniquely generated from the oxidation of docosahexaenoatecontaining lipids and are more abundant in the drusen and serum of subjects with AMD compared to subjects without AMD 19 . Recently, carboxyalkylpyrroles, among them CEP, have been shown to be recognized by TLR2 on endothelial cells 30 . Given that TLR2 activation would prime cells to induce pro-IL1β, pro-IL18 and NLRP3, we hypothesized that CEPadducted proteins in drusen and on the Bruch's membrane could represent a previously unidentified priming agent.
To test this hypothesis, we primed PBMCs with increasing con centrations of CEPadducted human serum albumin (CEPHSA) or HSA alone and activated the cells with ATP. The production of IL1β increased with increasing concentrations of CEPHSA, but we found no changes in the amount of IL1β in cells primed with HSA alone (Fig. 2a) . WT BMDMs primed with CEPHSA and activated with ATP also produced IL1β, an effect that we did not observe in Nlrp3 −/− BMDMs (Fig. 2b) . To ascertain whether CEPHSA was priming the cells through TLR2 activation, we primed WT and Tlr2 −/− BMDMs with HSA or CEPHSA and activated them with ATP. ATP activation induced increases in IL1β production in WT but not Tlr2 −/− BMDMs primed with CEPHSA. Furthermore, we found no IL1β induction in BMDMs from either group primed with HSA before ATP activation, again confirming that it is CEP modification that confers the ability to activate TLR2 (Fig. 2c) . IL6 concentrations were equivalent in ATPactivated and ATPunactivated WT cells treated with CEPHSA, confirming the specificity of the response for IL1β (Fig. 2d) .
We measured IL1β concentrations in LPSprimed WT and Tlr2 −/− BMDMs activated by ATP to ensure that the Tlr2 −/− BMDMs were responding optimally ( Supplementary Fig. 4 ). To ensure our CEP HSA was not contaminated with LPS, we isolated BMDMs from C3H/ HeN and C3H/HeJ mice. C3H/HeJ mice carry a mutation in their Tlr4 gene that renders them unresponsive to LPS 31 ; the C3H/HeN mice do not have this mutation. C3H/HeJ BMDMs produced IL1β in response to ATP when primed with CEPHSA but not when primed with LPS ( Fig. 2e) , indicating that our CEP adduct was LPS free and primed the inflammasome through TLR2 ligation. We detected TNFα in LPS primed, but not CEPprimed, C3H/HeN BMDMs (Fig. 2f) . We further examined the ability of CEPHSA to prime the NLRP3 inflamma some by measuring ASCYFP speck formation in CEPHSA-treated immortalized WT BMDMs. We found focused ASCYFP specks in BMDMs primed with CEPHSA and activated with drusen (Fig. 2g) . Drusen alone seemed to be able to cause the oligomerization of ASC (Fig. 2g) , implying that alone, drusen could initiate the formation of the multiprotein platform for inflammasome activation. However, we were unable to consistently detect increases in IL1β concentration when we treated PBMCs, WT BMDMs or WT BMDCs with drusen alone and assayed them using ELISA.
Drusen component C1Q activates the inflammasome
Although drusen can distort and eventually damage the retina, as is seen in geographic atrophy 29 , not all people presenting with drusen develop vision loss; therefore, it is conceivable that in addition to the particulate nature of drusen causing mechanical insult to the RPE, some component(s) of drusen may be involved in the activation of the inflammasome in a more specific manner. We elected to study C1Q, the primary initiating component of the classical complement pathway, which has been identified in drusen 32 . Because C1Q is an effector of the innate immune system and has the potential to be extremely damaging to host tissue, its presence in drusen is indica tive of an earlier or ongoing inflammatory insult. We directly evalu ated the ability of C1Q to activate the NLRP3 inflammasome. The addition of C1Q alone to WT BMDMs did not cause the production of IL1β, however, cells that we primed with CEPHSA before the addition of C1Q produced significant amounts of IL1β compared with C1Q alone (Fig. 3a) . Secretion of the proinflammatory cytokine TNFα was unchanged after addition of C1Q to CEPHSA-primed WT BMDMs (Fig. 3a) , indicating that C1Q was specifically activat ing the inflammasome and was not involved in the upregulation of proinflammatory cytokines in general. We found cleaved caspase1 p10 in THP1 human monocytic cells activated with C1Q ( Fig. 3b and  Supplementary Fig. 5 ) and further established that C1Q can cause ASC oligomerization, as we found YFPASC specks in concentrated focal points within the cells activated with C1Q after priming with either LPS or CEPHSA (Fig. 3c) .
WT BMDCs treated with C1Q produced significantly more IL1β than Nlrp3 −/− BMDCs, which did not produce IL1β in response to C1Q activation (Fig. 3d) ; the amount of TNFα was the same in both groups of BMDCs after C1Q activation (Fig. 3d) . To confirm the role of caspase1, we added a caspase1 inhibitor, ZVAD, to human PBMCs before activation with C1Q. Caspase1 inhibition decreased the production of both IL1β and IL18 in a dosedependent manner (Fig. 3e) . Together, these results show that C1Q can act as a danger signal that is sensed by the NLRP3 inflammasome. All C1Q isolated from human blood and found in drusen has a propensity to aggregate, which we have shown using a zetapotential analysis of a solution of C1Q, and we believe this is a key factor in how C1Q can activate the NLRP3 inflammasome (Supplementary Fig. 6 ).
C1Q inflammasome activation involves the phagolysosome
Deposits of C1Q, along with other complement factors, have been shown to be associated with amyloid structures or their compo nents 33, 34 . It is therefore probable that this characteristic of C1Q has a role in the aggregation of drusen. In addition, the function of C1Q in initiating opsonization would assist macrophages as they attempt to phagocytose these particulate drusen deposits. The mechanisms leading to NLRP3 inflammasome activation are unresolved and may depend on the stimulus. One proposed mechanism of NLRP3 acti vation involves the phagocytosis of particulate structures, leading to lysosomal rupture and the release of lysosomal contents 35 . Another pro posed mechanism involves the production of reactive oxygen species (ROS), leading to the activation of the NLRP3 inflammasome through the ROSsensitive thioredoxin interacting protein (TXNIP) 36 .
To determine whether the induction by C1Q of ROS 37, 38 was respon sible for the inflammasome activation seen in this study, we treated PBMCs with the NADPH oxidase inhibitor diphenyliodonium (DPI) before C1Q activation. Inhibition of ROS by DPI had no effect on C1Q induced IL1β release (Supplementary Fig. 7a ). Another alternative mechanism that has been proposed for inflammasome activation is lyso somal instability leading to the leakage of the lysosomal exopeptidase, cathepsin B, into the cytosol, which is then sensed by the components of the inflammasome, leading to its assembly 35 . To determine the role of the phagolysosome in the activation of the inflammasome by C1Q, we used bafilomycin A, an inhibitor that blocks the vacuolar H + ATPase system that is necessary for lysosomal acidification, and the cathepsin B inhibi tor CA074 Me. Inhibition of either vacuolar H + ATPase or cathepsin B restricted the C1Qactivated production of IL1β and IL18 with no effect on IL6 production ( Supplementary Fig. 7b,c) . This implies that C1Q alters the phagolysosomal process to trigger NLRP3 activation.
NLRP3 inflammasome is active in CEP-MSA-immunized mice
We sought to determine whether the inflammasome is involved in the pathology of a model of dry AMD, the CEPMSA-immunized mouse model. This mouse develops AMDlike lesions in its retina and RPE after immunization with CEPMSA. We analyzed retinal sections of CEPMSA-immunized mice for the presence of activated macrophages (indicated by F4/80 and CD68 stain ing), caspase1 p10 and NLRP3. We found activated macrophages within the choroid and Bruch's membrane in the retinas of these mice (Fig. 4a,b and Supplementary Fig. 8 ). We also found infiltrating macrophages above the RPE in the outer segments of the retinas (Fig. 4c) . Staining of these sections showed colocalization of F4/80 with cleaved caspase1 p10 (Fig. 4d,e) and NLRP3 (Fig. 4f,g and Supplementary Fig. 9 ).
NLRP3 protects against exacerbated laser-induced CNV
A model for wet (exudative) AMD is laserinduced CNV, which is also an ideal model for sterile inflammation 39 , probably because of the induction of a necrotic microenvironment within the tissue. Necrotic cells are known to trigger a sterile inflammatory response through the NLRP3 inflammasome 17 . We hypothesized that the NLRP3 inflammasome may have a key role in CNV development in response to localized tissue injury. To test our hypothesis, we administered focal laser burns to the retinas of WT, Nlrp3 −/− and Il1r1 −/− mice and assessed their CNV volumes. We found significantly more CNV development and subretinal hemorrhaging in Nlrp3 −/− mice compared to WT and Il1r1 −/− mice (Fig. 5a) . Threedimensional zstack confocal volume rendering of the CNV confirmed a significantly greater (P = 0.0496) CNV volume in Nlrp3 −/− mice 6 d after injury compared to WT and Il1r −/− mice (Fig. 5a ). An electroretinographic (ERG) analysis confirmed that both groups of knockout mice had functional rod and cone responses before injury (Fig. 5b) . We observed activated macrophage infiltra tion (positive F4/80 immunoreactivity) at the lesion sites in Nlrp3 −/− mice (Fig. 5c) , however, cleaved caspase1 and IL18 were only evi dent at the injury sites of WT mice and were notably absent at these sites in Nlrp3 −/− mice ( Fig. 5d and Supplementary Figs. 10 and 11) . These findings describe a role for the NLRP3 inflammasome in the sterile inflammatory response observed in this mouse model of CNV and point toward IL18 as a regulator of CNV development.
NLRP3 confers protection against CNV through IL-18
To confirm a role for IL18 in the NLRP3mediated protection against exacerbated CNV development, we administered laserinduced CNV to IL18 −/− mice. We found these mice to have normal retinal function (Fig. 6a) , as assessed by an ERG analysis. Laserinduced disruption of the Bruch's membrane and a CNV volume quantifica tion in IL18 −/− mice 6 d after injury showed markedly increased lesions in the CNV from these mice (Fig. 6b) than in the CNV from WT mice (Fig. 6c) . Intravitreally injecting IL18-neutralizing antibodies subsequent to laserinduced CNV also resulted in significantly (P = 0.0368) increased CNV development in injected WT mice compared to WT mice that were not injected (Supplementary Fig. 12 ).
We reasoned that IL18 might confer its protection through the regulation of vascular endothelial growth factor (VEGF) synthesis. To test this hypothesis, we treated ARPE19 cells and a mouse brain microvascular endothelial cell line (bEnd.3) with recombinant IL18 and then analyzed the VEGF concentrations in the growth medium. IL18 significantly decreased the amount of VEGF secreted by both ARPE19 and bEnd.3 cells (Fig. 6d,e) . These findings implicate a 
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-/-role for IL18 in the regulation of VEGF expression and could explain the exacerbated CNV in Nlrp3 −/− and IL18 −/− mice.
DISCUSSION
Here we describe a series of observations that could have major impli cations for the prevention of AMD. Current antibodybased therapies target advanced forms of AMD by inhibiting the bioactivity of VEGF. However, direct and regular intraocular injection of these monoclonal antibodies (Lucentis and Avastin) carries the risk of retinal detach ment, hemorrhage and infection 40 .
We have shown that drusen isolated from AMD donor eyes can activate the NLRP3 inflammasome. AMD drusen is composed of a collection of protein deposits, many of which are adducted to CEP. Because of its particulate nature, it is possible that drusen from normal donor eyes may also induce inflammasome activation, however the concentrations of normal drusen in the retina, by definition, are lower than the concentrations of AMD drusen, and the biochemical com positions of the two types of drusen are different. These differences are probably crucial for the progression of AMD 41 . A comparison of normal and AMD drusen in relation to inflammasome activation, however, has not yet been made.
We have shown that CEPHSA can prime the inflammasome through TLR2 activation, providing us with a naturally occurring priming agent that accumulates at focal points at high concentrations within the AMD eye. In the case of NLRP3, the danger signal is usually particulate and is extracellular in nature. C1Q, a component of drusen, has been shown to aggregate in an amyloidlike fashion 42 . We show that C1Q isolated from human blood activates the NLRP3 inflammasome in a manner that is dependent on lysosomal acidification and cathepsin B.
The sterile inflammatory response that occurs in AMD is prob ably a result of the focal necrosis that occurs in the RPE cells subad jacent to excessive drusen accumulation. Drusen accumulation in the Bruch's membrane is a hallmark feature and diagnostic indica tor of early AMD development and is thought to be central to the pathology of the disease. Although we observed inflammasome acti vation in macrophages associated with AMDlike lesions in CEP MSA-immunized mice, our observations indicate a protective role for inflammatory processes in the progression to CNV, the exudative form of AMD, and directly oppose the current dogma that is directed at the suppression of inflammatory processes in disease prevention. Indeed, it is now accepted that some amount of inflammation, so called 'parainflammation' , may be beneficial to the host 43, 44 . From a clinical perspective, although inflammatory processes have long been associated with AMD pathology and disease development, we suggest that global inhibition of inflammation in the retina in the case of wet AMD would not be a sound therapy. Lending strength to our obser vations, the results of recent clinical trials of infliximab (Remicade, which targets tumor necrosis factor α (TNFα)) in individuals with wet AMD 45, 46 showed that in more than 50% of these subjects, their symptoms were greatly exacerbated. The NLRP3 inflammasome has also recently been shown to confer protection, through IL18 produc tion, against experimental colitis and colorectal cancer in mice 47, 48 . Previous studies indicated that IL18 has a key role in retinal vascular development. Il18 −/− mice showed angiectasis and vascular leakage, and VEGF and basic fibroblast growth factor concentrations were also upregulated in the Il18 −/− mouse retinas 49, 50 . Antiangiogenic roles for IL18 have also been observed in postischemic injury 51 and in the inhibition of tumor angiogenesis 52 .
Activation of the NLRP3 inflammasome by drusen suggests that a balance may exist whereby a certain focal amount of drusen is tolerated because of its ability to induce IL18, which, in turn, may act as an antiangiogenic effector, maintaining choroidal homeostasis in an inflammatory microenvironment. It is probable that once a critical level of drusen accumulates, its protective role is negated by the excessive damage to the surrounding tissues that it causes. Notably, we have shown that druseninducible inflammatory medi ators are protective against CNV development and that it is the resultant NLRP3mediated elevation of IL18 concentrations that prevents the downstream production of VEGF. Moreover, IL18 has been shown not to have a role in the development of experimen tal uveitis, a more conventional model of inflammation, which has direct implications for future forms of therapy deriving from our findings 53 . Overall, our observations directly implicate NLRP3 as a protective agent against the major disease pathology of AMD and suggest that strategies aimed at producing or delivering IL18 to the eye may be beneficial in preventing the progression of CNV in the context of wet AMD.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
